New Approaches to Diabetic Nephropathy from Bed to Bench

Biomedicines

卷:10

Jun-Li Tsai¹  Ming-Ju Wu²  Cheng-Hsu Chen²  Shang-Feng Tsai² 

[1] Division of Family Medicine, Cheng Ching General Hospital, Taichung 407, Taiwan;

[2] Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan;

关键词: chronic kidney disease;    diabetic nephropathy;    hypoxia;    anemia;    hypoxia;    hypoxia-inducible factor (HIF);   

DOI  :  10.3390/biomedicines10040876

来源: DOAJ

【 摘 要 】

Diabetic nephropathy (DN) is the main cause of end-stage kidney disease (ESKD). DN-related ESKD has the worst prognosis for survival compared with other causes. Due to the complex mechanisms of DN and the heterogeneous presentations, unmet needs exist for the renal outcome of diabetes mellitus. Clinical evidence for treating DN is rather solid. For example, the first Kidney Disease: Improving Global Outcomes (KDIGO) guideline was published in October 2020: KDIGO Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. In December of 2020, the International Society of Nephrology published 60 (+1) breakthrough discoveries in nephrology. Among these breakthroughs, four important ones after 1980 were recognized, including glomerular hyperfiltration theory, renal protection by renin-angiotensin system inhibition, hypoxia-inducible factor, and sodium-glucose cotransporter 2 inhibitors. Here, we present a review on the pivotal and new mechanisms of DN from the implications of clinical studies and medications.

【 授权许可】

Unknown